Drug Trial Radar · NCT06335407
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jul 28, 2025
Primary completion
Feb 27, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders AllianceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Department of Defense; Congressionally Directed Medical Research Programs; VA Connecticut Healthcare System; BioXcel Therapeutics Inc; Yale University; RTI International
- First posted
- Mar 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.
Conditions
- Alcohol Use Disorder (AUD)
- Post Traumatic Stress Disorder (PTSD)
Interventions
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µgDrug
BXCL 501 40µg will be administered orally, as individual films in the Sub Lingual (SL) space.
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µgDrug
BXCL 501 80µg will be administered orally, as individual films in the SL space
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Blood Pressure (Systolic and Diastolic) from baseline (pre-treatment) through day 28.Time frame: From day 1 through day 28
- Change in anxiety (measured via the State Trait Anxiety Inventory - STAI-6) from baseline (pre-treatment) through day 28.Time frame: From day 1 through 28 days
- Number and Proportion of Adverse EventsTime frame: From day 1 through 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
VA Connecticut Healthcare System
West Haven, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.